Charting new territory in the multibillion-dollar market for medicines derived from living organisms, a federal appeals court for the first time will review the regulatory path for creating generic versions of high-tech — and high-cost — biologic drugs.
A three-judge panel of the U.S. Court of Appeals for the Federal Circuit on Sept. 10 will hear a suit by Sandoz Inc., which wants to make a copycat version of Amgen Inc.’s blockbuster arthritis drug Enbrel.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
